Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SI-B001 + FOLFOX
- Development stage
- Unknown
- Lead developer
- Biokin Pharmaceutical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
SI-B001 + FOLFOX is an investigational combination regimen consisting of SI-B001, a novel monoclonal antibody targeting the HER3 receptor (also known as ERBB3), administered alongside the established FOLFOX chemotherapy protocol. FOLFOX is a regimen including folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin, widely used for various solid tumors—primarily colorectal cancer, but also explored for other gastrointestinal and epithelial malignancies. The combination is being studied in advanced cancers such as non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck, with SI-B001 intended to block HER3-mediated signaling pathways that drive tumor growth and resistance to therapy, while FOLFOX delivers cytotoxic effects by interfering with DNA synthesis and repair in rapidly dividing cells[9][2][3][1].
- Other names
- SI-B001 plus FOLFOXSI-B-001 plus FOLFOXSI-B 001 plus FOLFOXSI-B001 combined with FOLFOXSI-B-001 combined with FOLFOXSI-B 001 combined with FOLFOX
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)DHFR (Dihydrofolate reductase)DNAEGFR T790M (Epidermal growth factor receptor T790M mutant)TS (Thymidylate synthase)
Beyond the preview
Go deeper on SI-B001 + FOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SI-B001 + FOLFOX.